At a glance
- Originator ARIAD Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bone cancer; Malignant hypercalcaemia
Most Recent Events
- 18 Nov 2003 Discontinued - Preclinical for Bone cancer in USA (unspecified route)
- 18 Nov 2003 Discontinued - Preclinical for Malignant hypercalcaemia in USA (unspecified route)
- 07 Jul 2003 Data presented at the 39th Annual Meeting of the American Society of Clinical Oncology (ASCO-2003) have been added to the Cancer pharmacodynamics section